Search

Displaying results 1271 - 1280 of 10000 in total
  1. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. … It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable

  2. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. … It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360].

  3. Drug

    Imipramine

    go.drugbank.com/drugs/DB00458
    ApprovedInvestigational

    In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. … Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label].

    Categories: Non-Selective Monoamine Reuptake InhibitorsSynonyms: 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine, N-(γ-dimethylaminopropyl)iminodibenzyl
  4. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    Some clinical data has suggested that the clinically recommended dose of 250mg was too low. … It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.

  5. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older.

  6. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood.

  7. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [A237520] Due to a paucity of effective safe and effective acute therapeutic agents, vaccination remains the most important defence against TBE in endemic areas. … Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable.

  8. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072

  9. Drug

    Dihydro-alpha-ergocryptine

    go.drugbank.com/drugs/DB11274
    Approved

    To know more about this mixture, please visit [DB01049]

  10. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    [A14416] Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery. … It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.